F Negro

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. pmc Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance
    Francesco Negro
    Viropathology Unit, University of Geneva Medical Center, 1211 Geneva, Switzerland
    PPAR Res 2009:483485. 2009
  2. pmc Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study
    Geert Bezemer
    Dpt, Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Gastroenterol 12:11. 2012
  3. doi request reprint Steatosis and insulin resistance in response to treatment of chronic hepatitis C
    F Negro
    Divisions of Gastroenterology and Hepatology and Clinical Pathology, University Hospitals, Geneva, Switzerland
    J Viral Hepat 19:42-7. 2012
  4. pmc Hepatitis C virus and type 2 diabetes
    Francesco Negro
    Division of Gastroenterology, Hepatology and Clinical Pathology, University Hospitals, Geneva 14, Switzerland
    World J Gastroenterol 15:1537-47. 2009
  5. doi request reprint Management of chronic hepatitis B: an update
    F Negro
    University Hospital Geneva, Geneva, Switzerland
    Swiss Med Wkly 141:w13264. 2011
  6. doi request reprint Mechanisms of hepatitis C virus-related insulin resistance
    Francesco Negro
    Departments of Internal Medicine and Pathology and Immunology, Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospitals, University of Geneva Medical Center, 1, rue Michel Servet, 1205 Geneva, Switzerland
    Clin Res Hepatol Gastroenterol 35:358-63. 2011
  7. doi request reprint Abnormalities of lipid metabolism in hepatitis C virus infection
    Francesco Negro
    Divisions of Clinical Pathology and of Gastroenterology and Hepatology, University Hospital, Rue Gabrielle Perret Gentil 4, 1211 Geneve 4, Switzerland
    Gut 59:1279-87. 2010
  8. doi request reprint Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data
    Francesco Negro
    Viropathology Unit, University Hospitals, Geneva, Switzerland
    Liver Int 29:26-37. 2009
  9. ncbi request reprint [What's new in the treatment of hepatitis B infection?]
    F Bihl
    Service de Gastroentérologie et d Hépatologie, Pr Francesco Negro Service de pathologie clinique, HUG, 1211 Geneve 14
    Rev Med Suisse 5:1720-2, 1724. 2009
  10. doi request reprint Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C
    F Negro
    Division of Clinical Pathology, University Hospitals, Geneva, Switzerland
    J Viral Hepat 16:681-8. 2009

Detail Information

Publications81

  1. pmc Peroxisome proliferator-activated receptors and hepatitis C virus-induced insulin resistance
    Francesco Negro
    Viropathology Unit, University of Geneva Medical Center, 1211 Geneva, Switzerland
    PPAR Res 2009:483485. 2009
    ..Whether and how this interaction may be manipulated pharmacologically, in order to improve the responsiveness to antivirals of insulin resistant chronic hepatitis C, patients remain to be fully explored...
  2. pmc Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study
    Geert Bezemer
    Dpt, Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
    BMC Gastroenterol 12:11. 2012
    ..HRQL improves after successful treatment. This trial explores the course of and factors associated with HRQL in patients given individualized or standard treatment based on early treatment response (Ditto-study)...
  3. doi request reprint Steatosis and insulin resistance in response to treatment of chronic hepatitis C
    F Negro
    Divisions of Gastroenterology and Hepatology and Clinical Pathology, University Hospitals, Geneva, Switzerland
    J Viral Hepat 19:42-7. 2012
    ..Similarly, viral insulin resistance may not reduce the rate of response to therapy to the same extent that metabolic insulin resistance does. Some implications for patient management are discussed...
  4. pmc Hepatitis C virus and type 2 diabetes
    Francesco Negro
    Division of Gastroenterology, Hepatology and Clinical Pathology, University Hospitals, Geneva 14, Switzerland
    World J Gastroenterol 15:1537-47. 2009
    ..Thus, a detailed knowledge of the mechanisms underlying the HCV-associated glucose metabolism derangements is warranted, in order to improve the clinical management of chronic hepatitis C patients...
  5. doi request reprint Management of chronic hepatitis B: an update
    F Negro
    University Hospital Geneva, Geneva, Switzerland
    Swiss Med Wkly 141:w13264. 2011
    ..With the potent drugs currently available, however, its management and control are possible in the majority of cases...
  6. doi request reprint Mechanisms of hepatitis C virus-related insulin resistance
    Francesco Negro
    Departments of Internal Medicine and Pathology and Immunology, Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospitals, University of Geneva Medical Center, 1, rue Michel Servet, 1205 Geneva, Switzerland
    Clin Res Hepatol Gastroenterol 35:358-63. 2011
    ..Thus, the molecular pathogenesis of glucose metabolism disturbances observed in hepatitis C is much more complex than expected. The clinical management of such condition remains empirical...
  7. doi request reprint Abnormalities of lipid metabolism in hepatitis C virus infection
    Francesco Negro
    Divisions of Clinical Pathology and of Gastroenterology and Hepatology, University Hospital, Rue Gabrielle Perret Gentil 4, 1211 Geneve 4, Switzerland
    Gut 59:1279-87. 2010
    ..As a result, lipid metabolism is overall altered, conferring an idiosyncratic profile to HCV infection. The scope of this review is to discuss these aspects, focusing on both their molecular mechanisms and their clinical consequences...
  8. doi request reprint Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data
    Francesco Negro
    Viropathology Unit, University Hospitals, Geneva, Switzerland
    Liver Int 29:26-37. 2009
    ....
  9. ncbi request reprint [What's new in the treatment of hepatitis B infection?]
    F Bihl
    Service de Gastroentérologie et d Hépatologie, Pr Francesco Negro Service de pathologie clinique, HUG, 1211 Geneve 14
    Rev Med Suisse 5:1720-2, 1724. 2009
    ..Once antiviral therapy has been started, patients need close monitoring to guarantee adequate compliance and to detect promptly the selection of viral variants resisting to therapy...
  10. doi request reprint Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C
    F Negro
    Division of Clinical Pathology, University Hospitals, Geneva, Switzerland
    J Viral Hepat 16:681-8. 2009
    ..We will review some of the current knowledge on the clinical consequences of overweight/obesity, steatosis and insulin resistance on chronic hepatitis C, and discuss how this issue may be dealt with in clinical practice...
  11. doi request reprint Hepatitis C virus-induced steatosis: an overview
    Francesco Negro
    Division of Gastroenterology and Hepatology, University of Geneva Medical Center, Geneva, Switzerland
    Dig Dis 28:294-9. 2010
    ..Other observations suggest that HCV may increase neolipogenesis and inhibit fatty acid degradation in mitochondria. Put together, all of these mechanisms contribute to the pathogenesis of fatty liver frequently observed in hepatitis C...
  12. ncbi request reprint IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation
    F Negro
    Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
    J Med Virol 56:224-9. 1998
    ..In conclusion, secretion of IgM anti-HCV core antibodies after OLT seems associated with recurrence of HCV-associated liver disease and may have diagnostic significance...
  13. doi request reprint Adverse effects of drugs in the treatment of viral hepatitis
    Francesco Negro
    Divisions of Clinical Pathology, University Hospitals, 24 Rue Micheli du Crest, 1211 Geneva 14, Switzerland
    Best Pract Res Clin Gastroenterol 24:183-92. 2010
    ..I will review the most common adverse events reported during the therapy of chronic hepatitis B and C, with some recommendations for proper management...
  14. ncbi request reprint Mechanisms and significance of liver steatosis in hepatitis C virus infection
    Francesco Negro
    Services de Gastroentérologie et d Hépatologie et de Pathologie Clinique, Geneve, Switzerland
    World J Gastroenterol 12:6756-65. 2006
    ..Management of steatosis in chronic hepatitis C requires knowledge of its pathogenesis and may involve both life-style changes and pharmacological interventions, although the latter remain largely experimental...
  15. ncbi request reprint Insulin resistance and HCV: will new knowledge modify clinical management?
    Francesco Negro
    Divisions of Gastroenterology and Hepatology and of Clinical Pathology, University Hospital, 24, Rue Micheli du Crest, 1211 Geneva 14, Switzerland
    J Hepatol 45:514-9. 2006
  16. ncbi request reprint Detection of hepatitis C virus RNA in liver tissue: an overview
    F Negro
    Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
    Ital J Gastroenterol Hepatol 30:205-10. 1998
    ....
  17. ncbi request reprint Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quantitative RT-PCR: preliminary application to the liver transplantation model
    F Negro
    Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
    J Hepatol 29:1-11. 1998
    ....
  18. ncbi request reprint Treatment of chronic hepatitis C with alpha-interferon plus ofloxacin in patients not responding to alpha-interferon alone
    F Negro
    Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
    J Hepatol 29:369-74. 1998
    ..Ofloxacin, a quinolone antibiotic, was recently shown to increase the primary response rate to alpha-interferon treatment of chronic hepatitis C...
  19. ncbi request reprint Liver steatosis in chronic hepatitis C: a morphological sign suggesting infection with HCV genotype 3
    L Rubbia-Brandt
    Division of Clinical Pathology, University Hospital, 1 rue Michel Servet, 1211 Geneva, Switzerland
    Histopathology 39:119-24. 2001
    ..To identify factors associated with liver steatosis in chronic hepatitis C...
  20. ncbi request reprint Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reverse-transcriptase polymerase chain reaction
    F Negro
    Divisions of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
    Hepatology 29:536-42. 1999
    ....
  21. ncbi request reprint Treatment of chronic hepatitis C
    F Bihl
    Divisions of Gastroenterology and Hepatology, University Hospital Geneva, Rue Gabrielle Perret Gentil 4, 1211 Geneva 14, Switzerland
    Minerva Med 100:459-65. 2009
    ..The advent of these drugs will further ameliorate response rates and facilitate the permanent cure of chronic hepatitis C...
  22. doi request reprint Pegylated interferon-alpha2a/ribavirin treatment of recurrent hepatitis C after liver transplantation
    S Dinges
    Division of Gastroenterology, University Hospital, Zurich, Switzerland
    Transpl Infect Dis 11:33-9. 2009
    ..03). A 48-week course of pegylated IFN-alpha(2a)/ribavirin therapy is effective in patients with recurrent HCV infection after LT...
  23. ncbi request reprint Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis
    F Negro
    Divisions of Gastroenterology and Hepatology, University Hospital, Geneva
    J Med Virol 60:21-7. 2000
    ..The exact mechanism of iron accumulation in these patients therefore remains unexplained...
  24. ncbi request reprint Are there any subgenomic forms of hepatitis C virus RNA in the liver?
    R Quadri
    Division of Gastroenterology, University of Geneva, School of Medicine, Switzerland
    Dig Liver Dis 33:480-6. 2001
    ..Hepatitis C virus has a single stranded positive RNA genoma. Although believed to replicate via semi-conservative transcription of a negative-stranded, genomic-length RNA intermediate, detailed steps of its replicative cycle are unknown...
  25. ncbi request reprint Nosocomial outbreak of multiple bloodborne viral infections
    S Yerly
    Laboratory of Virology, Division of Infectious Diseases, Geneva University Hospital, Geneva, Switzerland
    J Infect Dis 184:369-72. 2001
    ..HIV and HCV genotypic analyses identified a HIV monophyletic group, whereas 4 clusters of HCV sequences were identified. To our knowledge, this is the largest documented outbreak of nosocomial HIV transmission...
  26. doi request reprint Hepatitis C virus and glucose and lipid metabolism
    M Alaei
    Divisions of Gastroenterology and Hepatology, University Hospitals, Geneva, Switzerland
    Diabetes Metab 34:692-700. 2008
    ....
  27. pmc Steatosis affects chronic hepatitis C progression in a genotype specific way
    L Rubbia-Brandt
    Division of Clinical Pathology, Hopitaux Universitaires, Geneve, Switzerland
    Gut 53:406-12. 2004
    ..The aim of this study was to determine the relationship between steatosis and fibrosis in chronic hepatitis C as a function of viral genotype...
  28. ncbi request reprint Detection of the negative-strand hepatitis C virus RNA in tissues: implications for pathogenesis
    R Quadri
    Division of Gastroenterology and Hepatology, University Hospital, 24 rue Micheli-du-Crest, 1211 Geneva 14, Switzerland
    Antiviral Res 52:161-71. 2001
    ..However, in some patients, most notably those infected with HCV genotype 3, HCV may cause a cytopathic effect, consisting in the lipid accumulation within hepatocytes...
  29. ncbi request reprint Peroxisome proliferator-activated receptor-alpha and -gamma mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection
    A De Gottardi
    Services de gastroentérologie et d hépatologie, Hopitaux Universitaires, Geneva, Switzerland
    Aliment Pharmacol Ther 23:107-14. 2006
    ..Steatosis in chronic hepatitis C is associated with inflammation and accelerated fibrogenesis...
  30. ncbi request reprint Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV
    O T Rutschmann
    Division of Infectious Diseases and of Gastroenterology, University Hospital, Geneva, Switzerland
    J Infect Dis 177:783-5. 1998
    ..04). HCV RNA levels returned to baseline after 17 and 32 weeks of treatment. Thus, potent anti-HIV regimens with protease inhibitors may temporarily worsen HCV status despite improvement of HIV parameters...
  31. ncbi request reprint Primary hepatic diffuse large B-cell lymphoma in a patient with chronic hepatitis C
    L Rubbia-Brandt
    Division of Clinical Pathology, University Hospital, Geneva, Switzerland
    Am J Surg Pathol 23:1124-30. 1999
    ..High grade non-Hodgkin's lymphomas, although rare complications, have to be considered as part of the spectrum of hepatitis C virus-related hepatic lesions...
  32. doi request reprint Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C
    Christine Bernsmeier
    Department of Biomedicine, Division of Gastroenterology and Hepatology, University Hospital Basel, Hebelstrasse 20, CH 4031 Basel, Switzerland
    J Hepatol 49:429-40. 2008
    ..We have shown previously that protein phosphatase 2A (PP2A) is over-expressed in biopsies from patients with CHC. In this study, we tested if PP2A over-expression leads to insulin resistance...
  33. ncbi request reprint An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation
    Karim Abid
    Division of Gastroenterology and Hepatology, University Hospital, 24 Rue Micheli du Crest, CH 1211 Geneva, Switzerland
    J Hepatol 42:744-51. 2005
    ..To extend these observations, we established an in vitro model expressing the HCV core of different genotypes...
  34. ncbi request reprint Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation
    Emiliano Giostra
    Division of Gastroenterology and Hepatology, University Hospital of Geneva, Rue Micheli du Crest 24, 1211 Geneva, Switzerland
    Transpl Int 17:169-76. 2004
    ..In conclusion, patients with recurrent hepatitis C after LT might benefit from ribavirin/IFN-alpha therapy, provided that the treatment is tolerated for a sufficient duration of time...
  35. ncbi request reprint [Reactivation of hepatitis B associated with immunosuppression]
    N Goossens
    Service de gastroentérologie et hepatologie, Département des spécialités de médecine, HUG, 1211 Geneve 14
    Rev Med Suisse 9:1566, 1568-71. 2013
    ..In situations at high risk of viral reactivation prophylactic antiviral therapy is indicated and reduces morbidity and mortality related to viral hepatitis flares...
  36. ncbi request reprint [The challenges of HIV-HCV co-infection]
    J Ambrosioni
    Service de Maladies Infectieuses, HUG, Geneve
    Rev Med Suisse 8:905-10. 2012
    ..Pharmacological interactions and increased toxicity of antiretroviral drugs and anti-HCV drugs are challenging for clinicians, especially if the recently approved anti-HCV proteases are used...
  37. ncbi request reprint [New aspect in the treatment of chronic hepatis B]
    I Morard
    Division de gastroentérologie et d hépatologie Département de médecine interne HUG, 1211 Geneve
    Rev Med Suisse 1:2012, 2014-7. 2005
    ..Entecavir is a selective inhibitor of polymerase HBV and shows a better efficacy than lamivudine. It is well tolerated and is associated only with a weak risk of resistance, even after a prolonged treatment...
  38. ncbi request reprint [Dermatitis associated with the treatment of chronic hepatitis C]
    Jann Lubbe
    Service de Dermatologie, d hépatologie et de pathologie clinique, HUG, 1211 Geneve 14
    Rev Med Suisse 1:1081-2, 1084-5. 2005
    ..An etiologic link to ribavirin-mediated immunomodulation remains to be investigated...
  39. ncbi request reprint Hepatocellular adenoma and polycystic ovary syndrome
    Christian Toso
    Clinique et Policlinique de Chirurgie Digestive, Departement de Chirurgie, Hôpitaux Universitaires Genève, Rue Michelidu Crest, 24 CH 1211, Geneve
    Liver Int 23:35-7. 2003
    ..In view of this complication, we recommend a close screening of patients with such hormonal imbalance, especially those who are treated with high doses of hormones, with repeated liver tests and ultrasonographies...
  40. ncbi request reprint Lack of in vivo blockade of Fas- and TNFR1-mediated hepatocyte apoptosis by the hepatitis C virus
    Laura Rubbia-Brandt
    Division of Clinical Pathology, University Hospital, 1211 Geneva, Switzerland
    J Pathol 197:617-23. 2002
    ..In conclusion, an HCV-mediated, in vivo blockade of hepatocyte apoptosis via the Fas- or TNFR1-dependent pathways seems unlikely...
  41. ncbi request reprint Impaired hepatic mitochondrial oxidation using the 13C-methionine breath test in patients with macrovesicular steatosis and patients with cirrhosis
    Laurent Spahr
    Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
    Med Sci Monit 9:CR6-11. 2003
    ..In human steatosis, ultrastructural changes are reported in the absence of ethanol. Routine evaluation of mitochondrial function is difficult. We used a breath test to explore hepatic mitochondrial oxidation in vivo...
  42. ncbi request reprint [Hepatitis C and insulin resistance]
    Mariam Seirafi
    Service de Gastroentérologie et d Hépatologie, HUG, 1211 Geneve 14
    Rev Med Suisse 4:1859-62. 2008
    ..It is therefore crucial to recognize it in order to correct it...
  43. doi request reprint Hepatitis C viral kinetics in plasma and peripheral blood mononuclear cells during pegylated interferon-alpha2a/ribavirin therapy
    Paolo Pugnale
    Department of Pathology and Immunology, University of Geneva Medical Center, 1211 Geneva, Switzerland
    J Hepatol 48:932-8. 2008
    ..Analysis of hepatitis C virus (HCV) RNA kinetics in compartments other than plasma may help in understanding HCV replication and identifying clinically significant patterns of treatment response...
  44. ncbi request reprint [Therapy of chronic hepatitis B]
    F Negro
    Services de Gastroentérologie et d Hépatologie et de Pathologie Clinique, HUG, 1211 Geneve 14
    Rev Med Suisse 2:1981-2, 1984-5. 2006
    ..Two inhibitors of HIV (tenofovir and emtricitabine) may also be used to treat hepatitis B in selected cases. Drug combinations, although supported by theoretical considerations, bring no known clinical benefit and are not reimbursed...
  45. doi request reprint Deficiency in the NADPH oxidase 4 predisposes towards diet-induced obesity
    Y Li
    Department of Cellular Physiology and Metabolism, University of Geneva, Geneva, Switzerland
    Int J Obes (Lond) 36:1503-13. 2012
    ..Our study was aimed at investigating the role of NOX4 in adipose tissue differentiation, whole body metabolic homeostasis and insulin sensitivity in vivo...
  46. doi request reprint Pioglitazone in chronic hepatitis C not responding to pegylated interferon-alpha and ribavirin
    Kathrin Overbeck
    Division of Clinical Pathology, University Hospital, 24 Rue Micheli du Crest, 1211 Geneva 4, Switzerland
    J Hepatol 49:295-8. 2008
    ..It has been speculated that improvement of insulin sensitivity might increase the chances of responding to treatment of such individuals...
  47. doi request reprint The hepatitis C virus core protein indirectly induces alpha-smooth muscle actin expression in hepatic stellate cells via interleukin-8
    Sophie Clement
    Division of Clinical Pathology, Geneva University Hospital, 1 rue Michel Servet, 1211 Geneva 4, Switzerland
    J Hepatol 52:635-43. 2010
    ..e., to be mediated by virally-driven inflammation, a direct role of HCV in inducing fibrosis deposition has never been entirely excluded...
  48. doi request reprint Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes
    Sophie Clement
    Division of Clinical Pathology, Geneva University Hospital, University of Geneva, Geneva, Switzerland
    Hepatology 48:799-807. 2008
    ..Investigation of the mechanism leading to the triglyceride accumulation showed that both a diminution of apolipoprotein B secretion and an increase in phosphoenolpyruvate carboxykinase messenger RNA may be involved...
  49. ncbi request reprint Immunological and virological effects of ribavirin in hepatitis C after liver transplantation
    Rafael Quadri
    Division of Gastroenterology and Hepatology, University Hospital, 1211 Geneva, Switzerland
    Transplantation 73:373-8. 2002
    ..A better understanding of the mechanisms of action of drugs currently used to manage hepatitis C would be helpful...
  50. ncbi request reprint Acute valproate-associated microvesicular steatosis: could the [13C]methionine breath test be useful to assess liver mitochondrial function?
    L Spahr
    Division of Gastroenterology and Hepatology, University Hospital, Geneva, Switzerland
    Dig Dis Sci 46:2758-61. 2001
    ..In conclusion, this observation suggests that the [13C]methionine breath test may provide a noninvasive estimate of hepatic mitochondrial function in vivo...
  51. doi request reprint The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians
    Florian Bihl
    Division of Gastroenterology and Hepatology, Geneva University Hospitals, 4 rue Perret Gentil, Geneva, Switzerland
    Swiss Med Wkly 140:154-9. 2010
    ..Once therapy has been started, the infection evolves and resistant viral strains may emerge. Rescue therapy needs to be started early with more potent agents lacking cross-resistance...
  52. ncbi request reprint Real-time multiplex PCR assay to quantify hepatitis C virus RNA in peripheral blood mononuclear cells
    Paolo Pugnale
    Division of Clinical Pathology, University Hospital, Geneva, Switzerland
    J Virol Methods 133:195-204. 2006
    ..0 (Roche) (R(2) = 0.977). In conclusion, this assay provides an excellent tool to determine accurately HCV kinetics in PBMCs during antiviral therapy and to assess the long-term significance of different patterns of response to treatment...
  53. ncbi request reprint The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms
    Valerio Pazienza
    Division of Clinical Pathology, University Hospital, Geneva, Switzerland
    Hepatology 45:1164-71. 2007
    ..We confirmed these findings by using agonists for PPARgamma (rosiglitazone) or short interfering RNAs for SOCS-7...
  54. doi request reprint Hepatitis delta virus inhibits alpha interferon signaling
    Paolo Pugnale
    Division of Clinical Pathology, University Hospital, Geneva, Switzerland
    Hepatology 49:398-406. 2009
    ..Interference of HDV with IFN-alpha signaling could represent an important mechanism of viral persistence and treatment resistance...
  55. doi request reprint Gene expression profile of Huh-7 cells expressing hepatitis C virus genotype 1b or 3a core proteins
    Valerio Pazienza
    Division of Clinical Pathology, University Hospitals and University of Geneva, Geneva, Switzerland
    Liver Int 29:661-9. 2009
    ..The liver disease expression in chronic hepatitis C patients is variable and may partially depend on the sequence of the infecting viral genotype...
  56. ncbi request reprint How should we treat recurrent hepatitis C after liver transplantation?
    Isabelle Morard
    Division of Gastroenterology and Hepatology, University Hospital, Rue Micheli du Crest 24, 1211 Geneva 14, Switzerland
    J Hepatol 42:462-8. 2005
  57. ncbi request reprint Barriers to interferon-alpha therapy are higher in intravenous drug users than in other patients with acute hepatitis C
    Barbara Broers
    Département de médecine communautaire, University Hospitals, Geneva, Switzerland
    J Hepatol 42:323-8. 2005
    ..Treatment with interferon-alpha (IFN-alpha) may eradicate HCV in most acute hepatitis C patients, thus preventing chronic hepatitis and avoiding less efficacious combination therapy...
  58. ncbi request reprint Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection
    Ana I Romero
    Department of Virology, University of Goteborg, Goteborg, Sweden
    J Infect Dis 194:895-903. 2006
    ..We investigated associations between interferon (IFN)-gamma-inducible protein (IP)-10 and liver histological results, viral kinetic response, and treatment outcome in patients infected with hepatitis C virus (HCV) genotypes 1-4...
  59. ncbi request reprint Hepatitis C virus and liver steatosis: when fat is not beautiful
    Francesco Negro
    J Hepatol 40:533-5. 2004
  60. ncbi request reprint International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C
    Stefan Zeuzem
    Saarland University Hospital, Homburg Saar, Germany
    J Hepatol 43:250-7. 2005
    ..The aim of this study was to increase virologic response rates by individualized treatment according to the early virologic response...
  61. ncbi request reprint Molecular evidence that the hepatitis C virus replicates in the oral mucosa
    Marco Carrozzo
    Department of Clinical Physiopathology, Section of Oral Medicine, University of Turin, Turin, Italy
    J Hepatol 37:364-9. 2002
    ..Our aim was to evaluate the HCV replication in oral mucosa of chronic hepatitis C patients...
  62. ncbi request reprint Hepatitis C virus genotype 1 associated with massive steatosis of the liver and hypo-beta-lipoproteinemia
    Guido Colloredo
    J Hepatol 40:562-3. 2004
  63. ncbi request reprint Alcohol is an important co-factor for both steatosis and fibrosis in Northern Italian patients with chronic hepatitis C
    Paolo Fabris
    Department of Infectious Diseases and Tropical Medicine, S Bortolo Hospital, Viale Rodolfi 37, Vicenza, Italy
    J Hepatol 41:644-51. 2004
    ..To evaluate: (1) the relationship between steatosis and either host or viral factors; (2) the correlation between steatosis and fibrosis in patients with CHC...
  64. ncbi request reprint Steatosis in chronic hepatitis C: friend or foe?
    Francesco Negro
    Liver Int 28:294-6. 2008
  65. ncbi request reprint Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3
    Hossein Poustchi
    Storr Liver Unit, Westmead Millennium Institute, University of Sydney and Westmead Hospital, NSW, Australia
    J Hepatol 48:28-34. 2008
    ..The aim of this study was to determine the relationship between the insulin resistance frequently seen in obese subjects and sustained virological response to anti-viral therapy (SVR) in patients with genotype 2 or 3 infection...
  66. ncbi request reprint Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C
    Caroline Hora
    Department of Clinical Pharmacology, University of Bern, Bern, Switzerland
    Liver Int 28:370-6. 2008
    ..We hypothesized that CTGF may link steatosis, insulin resistance and fibrosis...
  67. ncbi request reprint Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data
    Gioacchino Leandro
    IRCSS de Bellis, Castellana Grotte, Italy
    Gastroenterology 130:1636-42. 2006
    ..We evaluated the association between steatosis and fibrosis and their common correlates in persons with CHC and in subgroup analyses according to hepatitis C virus (HCV) genotype and body mass index...
  68. pmc Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress
    Gulam Waris
    Department of Medicine, Division of Infectious Diseases, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA
    J Virol 81:8122-30. 2007
    ..Collectively, these studies provide insight into the mechanisms of hepatic steatosis associated with HCV infection...
  69. ncbi request reprint HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project)
    Massimo Pilli
    Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    Gastroenterology 133:1132-43. 2007
    ....
  70. ncbi request reprint Antigenic relevance of F protein in chronic hepatitis C virus infection
    Florence Komurian-Pradel
    UMR2142 CNRS bioMérieux, IFR 128 Biosciences Lyon Gerland, Lyon, France
    Hepatology 40:900-9. 2004
    ..In conclusion, the F protein elicits specific antibodies in 62% of individuals chronically infected with HCV; such anti-F response does not seem to be affected by the F sequence heterogeneity...
  71. ncbi request reprint The 4,977-base pair common deletion of mitochondrial DNA is not associated with steatosis in chronic hepatitis C patients
    Patrizia Latorre
    Hepatology 35:239-40. 2002
  72. ncbi request reprint IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
    Martin Lagging
    Department of Infectious Diseases, University of Goteborg, Sweden
    Hepatology 44:1617-25. 2006
    ..Thus, pretreatment IP-10 analysis may prove helpful in decision-making regarding pharmaceutical intervention...
  73. ncbi request reprint Optimized vaccination regimen linked to exhaustive screening approaches identifies 2 novel HLA-B7 restricted epitopes within hepatitis C virus NS3 protein
    Perrine Martin
    IFR128 BioSciences Gerland, Lyon, France
    Microbes Infect 8:2432-41. 2006
    ..Such epitopes enlarge the pool of NS3-specific CD8+T cell epitopes available to perform immunomonitoring of HCV infection and to develop vaccines...
  74. ncbi request reprint In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease
    Rong Liu
    Department of Virology, Schering Plough Research Institute, Kenilworth, NJ 07033, USA
    J Antimicrob Chemother 59:51-8. 2007
    ..The aim of this study was to evaluate the in vitro antiviral activity of SCH446211...
  75. ncbi request reprint Lack of evidence for ribavirin-induced bone loss
    Andrea Trombetti
    Hepatology 36:255-7. 2002
  76. ncbi request reprint Hepatitis C virus: the viral way to fatty liver
    Sophie Clement
    J Hepatol 46:985-7. 2007
  77. ncbi request reprint Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS)
    Leonie Prasad
    Department of Social and Preventive Medicine, Division of Epidemiology and Biostatistics, Finkenhubelweg 11, 3012 Bern, Switzerland
    Int J Epidemiol 36:731-7. 2007
  78. ncbi request reprint [Our friend...coffee]
    Antoine Hadengue
    Rev Med Suisse 3:1931. 2007
  79. ncbi request reprint Hepatitis C virus and liver steatosis: is it the virus? Yes it is, but not always
    Francesco Negro
    Hepatology 36:1050-2. 2002
  80. ncbi request reprint Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response
    Massimo Pilli
    Divisione Malattie Infettive ed Epatologia, Azienda Ospedaliera Universitaria di Parma, Parma, Italy
    Hepatology 36:1446-52. 2002
    ..In conclusion, this finding and the detection of HCV RNA strands in the lichen tissue strongly suggest a role for HCV-specific T-cell responses in the pathogenesis of oral lichen planus associated with HCV infection...
  81. pmc Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras
    Thomas Pietschmann
    Department of Molecular Virology, University of Heidelberg, Im Neuenheimer Feld 345, 69120 Heidelberg, Germany
    Proc Natl Acad Sci U S A 103:7408-13. 2006
    ..Finally, we describe an E1-specific antiserum capable of neutralizing infectivity of all HCV chimeras...